Studies

Showing 30 studies.

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

Research Area

Study Status

IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV

DAIDS Number

Research Area

Study Status

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2017: MOCHA

DAIDS Number

Research Area

Study Status

Closed to Accrual

IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

DAIDS Number

Research Area

Study Status

P1113: AERAS-404 TB Vaccine in BCG-Primed Infants

DAIDS Number

Research Area

Study Status

Closed to Follow Up

P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls

DAIDS Number

Research Area

Brain and Mental Health

Study Status

Participants Off Study and Primary Analysis Completed

P1089: Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Chldren/youth

DAIDS Number

Research Area

Study Status

P1088: H1N1 INFLUENZA VACCINE IN HIV-INFECTED CHILDREN AND ADOLESCENTS

DAIDS Number

Research Area

Study Status